IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report released on Friday. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of IRIX stock opened at $1.67 on Friday. The company has a 50 day simple moving average of $1.66 and a two-hundred day simple moving average of $1.84. The stock has a market cap of $27.78 million, a P/E ratio of -2.49 and a beta of 0.81. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The company had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same quarter in the prior year, the company posted ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.